Insights - The latest COVID variant Omicron has been detected in at least 5 US states, with more expected. Worldwide headlines of this variant have caused uncertainty … Continue Reading
PremiumInsights - Affimed reported surprise data this morning for AFM13+NK cells with partner MD Anderson. This is the data that was expected in mid-December, which now the company will … Continue Reading
PremiumInsights - Eloxx (ELOX) shared monotherapy data from their Phase 2 in cystic fibrosis this morning. The data that was reported was not bad, but it left investors wanting … Continue Reading
PremiumInsights - Medicenna (MDNA) reported a business update late last week. Biomarker data continues to be on schedule for end of year 2021 and initial efficacy data … Continue Reading
PremiumInsights - Eloxx (ELOX) reported Q3 business update last week which caused the stock to trade lower, presumably because combination data was pushed back from Q1 2022 … Continue Reading
PremiumInsights - Affimed (AFMD) announced a few updates this morning with ASH nearing. Overall, little substance was shared, which was disappointing as we were expecting AFM13+NK data … Continue Reading
PremiumResearch - The biotech route has been long and painful. Actually, the longest drawdown in XBI since its inception, going on for over 8 months now. XBI … Continue Reading
Premium
